Figure 7

Higher concentration of sorafenib induced UPR pathway associated with IRE1α-XBP1s axis. (a,b) Western blot analysis showing IRE1α, pIRE1α, GRP78 (BiP), calreticulin and XBP1s expression after treatment with 10 µM sorafenib treatment for 12 h and 24 h. αTubulin and GAPDH were used as a loading control. The immunoblots were depicted the influence of inhibitor of IRE1α 3-Ethoxy-5,6-dibromosalicylaldehyde (EDBS) on 10 µM sorafenib induced protein level of IRE1α, pIRE1α, GRP78 (BiP), calreticulin and XBP1s. (c,d) Protein expression level were quantified using ImageJ software. GAPDH and αTubulin were used as a loading control. Relative protein ratios (normalized with loading control) were shown in a plot graph. Data represent mean ± s.d. from three independent experiments (ns > 0.05, *P < 0.05; **P < 0.01, ***P < 0.001 One-way analysis of variance).